

In Vitro Activity of Tigecycline and Comparators Against Difficult-to-Treat European Isolates

R. Badal¹, D. Hoban¹, B. Johnson¹, S. Bouchillon¹, M. Hackel¹, J. Johnson¹, M. Dowzicky²

¹International Health Management Associates, Schaumburg, IL, USA
²Wyeth Pharmaceuticals, Collegeville, PA, USA

IHMA, Inc.
2122 Palmer Dr.
Schaumburg, IL 60173
Tel: (847) 303-5003
Fax: (847) 303-5601
www.ihmainc.com

REVISED ABSTRACT

Background: Enhanced activity agents such as tigecycline (TIG) may offer antibacterial coverage of common pathogens including multi-drug resistant gram-negatives/positives. The T.E.S.T. program monitored the in vitro activity of TIG and comparators against current European pathogens. **Methods:** For this study, 42 hospital sites in 16 European countries collected over 9,400 significant isolates from community/hospital infection sites. MICs were determined to TIG and comparators using broth microdilution panels (EUCAST specified and interpreted). **Results:** Selected European pathogens tested against tigecycline are shown below:

Organism (n)	Tigecycline		Cumul. % inhibited at MIC				%S*
	MIC ₅₀	MIC ₉₀	0.5	1	2	4	
<i>A. baumannii</i> (669)	0.25	1	80.3	96.3	99	100	na
<i>E. faecalis</i> (679)	0.12	0.25	100				100
EC, KO, KP ^a (3,056)	0.25	1	89.8	95.5	97.8	99.7	95.5
ESBL ^b (276)	0.5	2	75.4	86.2	93.1	97.8	86.2
<i>Enterobacter</i> spp. (1,455)	0.5	2	74.9	88.5	94.6	99.2	88.5
<i>P. aeruginosa</i> (1,236)	8	>16	1.5	3.2	7.8	25.4	na
<i>S. aureus</i> (MR) (337)	0.12	0.25	100				100

* EC - *E. coli*, KO - *K. oxytoca*, KP - *K. pneumoniae*
* ESBL producing EC, KO and KP
* Interpretive criteria as defined by EUCAST, where available; CLSI breakpoints, where available, were used where no EUCAST breakpoints exist; na = not available.

Conclusion: Potentially difficult-to-treat European isolates of both gram-positive/negative community/hospital pathogens demonstrated generally excellent TIG MIC₉₀s and % susceptible (excluding *Pseudomonas*). For most organisms/phenotypes, TIG MIC₉₀s were ≤1 mcg/ml and % susceptible >90%. TIG activity was reduced against European ESBL-producing *Enterobacteriaceae* isolates (MIC₅₀ = 2; S = 86.2). TIG promises expanded broad spectrum activity against multiply resistant European pathogens.

INTRODUCTION

Tigecycline is a novel antimicrobial with expanded broad-spectrum activity from a new class of compounds, the glycylcyclines. Tigecycline inhibits protein synthesis by binding to the 30S ribosomal subunit. Although it is perceived to be bacteriostatic, its anti-bacterial activity is significant and has shown some bactericidal activity against key targeted pathogens [1,2]. Tigecycline was developed to provide activity against tetracycline and multi-drug-resistant gram-positive pathogens and has demonstrated significant broad-spectrum activity against aerobic and anaerobic gram-positive and gram-negative microorganisms [2-4].

Tigecycline resistance is very infrequent and is also difficult to induce in the laboratory [5, 6] with a selection frequency observed at less than 10⁻⁸ [3, 5, 7]. With the exception of *P. aeruginosa*, tetracycline-resistant bacteria with either tetracycline efflux pumps or ribosomal protective features are sensitive to tigecycline [2-4, 7-11]. Tigecycline has shown to be a highly effective against multi-resistant *Acinetobacter* spp., particularly *A. baumannii* that are commonly associated with serious nosocomial infections. Similar activity has been observed against *Enterobacteriaceae*, even extended-spectrum beta-lactamase (ESBL) and AmpC producing strains [10]. Tigecycline has demonstrated MIC₉₀ values of ≤0.5 mcg/ml against methicillin-resistant *Staphylococcus aureus* (MRSA) and other gram-positive organisms [2, 4-6]. Tigecycline has shown potent activity against animal models infected with selected strains of multi-drug resistant *Enterococcus faecium* and *Enterococcus faecalis* [4, 5] with diverse genotypes van-A, -B and -C [6].

The T.E.S.T. program determined the in vitro activity of tigecycline compared to most commonly prescribed broad spectrum antimicrobials against gram-negative and gram-positive species collected from 205 hospitals globally from 2004 to 2006. This study was designed to evaluate the in vitro activity of tigecycline against potentially difficult-to-treat organisms collected in Europe.

MATERIALS & METHODS

- For the T.E.S.T program all isolates were derived from blood, respiratory tract, urine (no more than 25% of all isolates), skin, wound, fluids, and other defined sources. Only one isolate per patient was accepted.
- For this study 9,435 clinical isolates were collected from 2004 to 2006 from 42 hospitals in 16 European countries (Austria, Belgium, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Poland, Portugal, Spain, Sweden, Switzerland, The Netherlands, and the United Kingdom).
- Minimum inhibitory concentrations (MICs) were determined by the CLSI recommended broth microdilution testing method [12]. Tigecycline was supplied by Wyeth Pharmaceuticals (Collegeville, PA, USA). All other agents were supplied by the panel manufacturer, MicroScan (Dade Behring Inc., Sacramento, CA, USA). The following antimicrobial agents were included on the panels with their dilution ranges (expressed in mcg/ml): amikacin (0.5-64); amoxicillin/clavulanic acid (0.12/0.06-32/16); ampicillin (0.5-32, gram-negative panel, and 0.06-16, gram-positive panel); cefepime (0.5-32); ceftazidime (0.5-32); ceftriaxone (0.06-64); imipenem (0.06-16); linezolid (0.5-8); levofloxacin (0.008-8); minocycline (0.5-16); tigecycline (0.008-16); penicillin (0.06-8); piperacillin/tazobactam (0.06/4-128/4) and vancomycin (0.12-32).
- MIC interpretive criteria followed published guidelines established by EUCAST where applicable; if no EUCAST guidelines were available for a given antimicrobial, CLSI guidelines [13] were used instead.
- Isolates were identified to genus and species by the local laboratory. Each site tested the isolates using broth microdilution.
- Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca* were screened for ESBL activity when MIC results for ceftazidime were >1mcg/ml using broth microdilution panels. ESBL activity was confirmed using the CLSI (2006) phenotypic confirmatory disk test (Oxoid, Ogdensburg, NY, USA) on Mueller-Hinton agar (Remel Inc., Lenexa, KS, USA) according to CLSI (2006) guidelines. ESBL presence was confirmed by testing the following antibiotic disks: cefotaxime (30-mcg), ceftazidime/clavulanic acid (30/10-mcg), ceftazidime (30-mcg), and ceftazidime/clavulanic acid (30/10-mcg). Antimicrobial disks were manufactured by Oxoid, Inc. (Ogdensburg, NY, USA). Mueller-Hinton agar used in testing was manufactured by Remel, Inc. (Lenexa, KS, USA). An organism was interpreted as containing an ESBL if there was an increase of >5 mm in the inhibition zone of the combination disk when compared to that of the cephalosporin alone.
- Quality control of broth microdilution panels followed manufacturer's and CLSI guidelines using the following ATCC strains: *Enterococcus faecalis* ATCC 29212; *Escherichia coli* ATCC 25922; *K. pneumoniae* ATCC 700603; *Haemophilus influenzae* ATCC 49247; *Haemophilus influenzae* ATCC 49766; *Staphylococcus aureus* ATCC 29213; *Streptococcus pneumoniae* ATCC 49619; and *Pseudomonas aeruginosa* ATCC 27853.
- The collection and transportation of organisms, confirmation of identification, and construction and management of a centralized database were conducted and coordinated by Laboratories International for Microbiology Studies (LIMS), a subsidiary of International Health Management Associates, Inc. (IHMA, Schaumburg, IL, USA).

REFERENCES

- Sum, P.E. and P. Petersen, *Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936*. Bioorg Med Chem Lett, 1999, 9(10): p. 1459-62.
- Abbanat, D., M. Macielag, and K. Bush, *Novel antibacterial agents for the treatment of serious Gram-positive infections*. Expert Opin Investig Drugs, 2003, 12(3): p. 379-99.
- Betriu, C., et al., *In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain*. Antimicrob Agents Chemother, 2002, 46(3): p. 892-5.
- Gates, A.C. and R.N. Jones, *Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates*. Diagn Microbiol Infect Dis, 2000, 36(1): p. 19-36.
- Henwood, C.J., et al., *Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)*. J Antimicrob Chemother, 2002, 49(3): p. 479-87.
- Chopra, I., *New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors*. Drug Resist Updat, 2002, 5(3-4): p. 119-25.
- Projan, S.J., *Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent*. Pharmacotherapy, 2000, 20(9 Pt 2): p. 219S-223S; discussion 224S-228S.
- Biedenbach, D.J., M.L. Beach, and R.N. Jones, *In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases*. Diagn Microbiol Infect Dis, 2001, 40(4): p. 173-7.
- Patel, R., et al., *In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae*. Diagn Microbiol Infect Dis, 2000, 38(3): p. 177-9.
- Petersen, P.J., et al., *In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936)*. Antimicrob Agents Chemother, 1999, 43(4): p. 738-44.
- Petersen, P.J., et al., *In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens*. Antimicrob Agents Chemother, 2002, 46(8): p. 2595-601.
- CLSI, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Sixth Edition, in Document M7-A6*. 2005: Clinical Laboratory Standards Institute (CLSI), 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
- Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth International Supplement*. CLSI document M100-S16. Wayne, PA, 2006.
- Tygacil®, 2005. *Tigecycline FDA package insert*.

ACKNOWLEDGEMENTS

This study was supported by a grant from Wyeth Pharmaceuticals.
We gratefully acknowledge contributions from the participants in the T.E.S.T. program who have helped make this program a success.

RESULTS

The results are listed in the following tables.

Table 1. In vitro activity of tigecycline and comparative agents against selected gram-negative organisms.

Organism (n)		MIC		Cumulative % inhibited				%S*	%I	%R	
		(mcg/ml)		at MIC							
		MIC ₅₀	MIC ₉₀	0.5	1	2	4				
<i>E. coli</i> ^a (1,572)	Tigecycline	0.12	0.25	99.2	99.9	100		99.9	0.1	0	
	Amikacin	2	4	1.5	18.8	70.7	91	97.2	1.7	1.1	
	AmoxClav	8	32	0.6	3.5	26.1	47.8	71.6	15.8	12.7	
	Ampicillin	>32	>32	0.7	6.9	30.5	39.9	40.8	0.4	58.7	
	Cefepime	≤0.5	4	85.8	88	89.7	91.7	88	5.7	6.3	
	Ceftazidime	≤8	≤8	0	0	0	0	0	94	6	
	Ceftriaxone	≤0.06	16	87.2	87.8	88.6	89.1	87.8	0.8	11.4	
	Imipenem	0.25	0.5	99.1	99.6	99.9	100	99.9	0.1	0	
	Levofloxacin	0.03	>8	75.6	76.1	77.2	81.4	76.1	1.1	22.8	
	Minocycline	1	8	36.3	60.8	74.2	83.5	83.5	9.5	7	
	PipTazo	1	8	29	68.6	83.9	88.2	93.6	2.8	3.6	
	<i>Klebsiella</i> spp. ^b (1,512)	Tigecycline	0.5	1	79.6	90.8	95.5	99.3	90.8	4.7	4.5
		Amikacin	2	4	3.4	47.4	83.7	90.3	94.6	2.7	2.6
AmoxClav		4	32	0.7	10.1	49.3	66.5	75.5	10.3	14.2	
Ampicillin		>32	>32	0	0	0	0	0	14.1	85.9	
Cefepime		≤0.5	8	79.2	83	86.3	89.3	83	8.5	8.5	
Ceftazidime		≤8	32	0	0	0	0	0	86	14	
Ceftriaxone		≤0.06	32	78.2	78.8	80.2	82.6	78.8	1.5	19.8	
Imipenem		0.25	0.5	94.4	98.4	99.5	100	99.5	0.5	0	
Levofloxacin		0.06	4	82.3	86.1	88.6	92.5	86.1	2.4	11.4	
Minocycline		2	16	9.1	46.5	71.2	82	82	6.4	11.6	
PipTazo		2	128	18.7	48.3	69.8	77.9	85.3	3.7	11	
ESBL-producers ^c (276)		Tigecycline	0.5	2	75.4	86.2	93.1	97.8	86.2	6.9	6.9
		Amikacin	4	32	1.1	14.1	36.2	52.9	74.3	14.1	11.6
	AmoxClav	16	>32	0.4	0.4	1.1	4.3	28.6	35.1	36.2	
	Ampicillin	>32	>32	0	0	0	0	0	0	99.3	
	Cefepime	16	>32	4.3	12	21.7	35.5	12	37.3	50.7	
	Ceftazidime	32	>32	0	0	0	0	0	28.6	71.4	
	Ceftriaxone	64	>64	2.5	3.3	5.1	10.5	3.3	1.8	94.9	
	Imipenem	0.25	0.5	95.3	97.8	99.3	100	99.3	0.7	0	
	Levofloxacin	4	>8	34.1	38.4	41.3	52.9	38.4	2.9	58.7	
	Minocycline	4	>16	6.9	23.6	42	60.5	60.5	13.4	26.1	
	PipTazo	8	>128	2.9	13	34.1	43.1	67	12.7	20.3	
	<i>Enterobacter</i> spp. (1,455)	Tigecycline	0.5	2	74.9	88.5	94.6	99.2	88.5	6.1	5.4
		Amikacin	2	4	1.4	40.7	82.3	90.8	95.6	2.7	1.6
AmoxClav		>32	>32	0	0	1.5	0.6	2	1.8	96.2	
Ampicillin		>32	>32	0	0	0	0	0	5.5	94.5	
Cefepime		≤0.5	8	65.2	73.5	80.8	88	73.5	19.4	7.1	
Ceftazidime		≤8	>32	0	0	0	0	0	62.7	37.3	
Ceftriaxone		0.5	64	53.7	57.2	60.5	64.4	57.2	3.3	39.5	
Imipenem		0.5	1	72.4	94.3	98.7	100	98.7	1.3	0	
Levofloxacin		0.06	>8	78.4	80.8	83.3	86.3	80.8	2.5	16.7	
Minocycline		2	8	2.8	14.8	55.7	82.1	82.1	10.6	7.4	
PipTazo		2	128	8	32	51.5	58.5	72.5	14.9	12.6	
<i>A. baumannii</i> (669)		Tigecycline	0.25	1	80.3	96.3	99	100	na	na	na
		Amikacin	4	>64	1.9	14.3	43.6	64.3	70.3	4.6	25.1
	Cefepime	8	32	3.9	10.6	26.2	40.2	56.2	17.9	25.9	
	Ceftazidime	≤8	>32	0	0	0	0	54	9.1	36.9	
	Ceftriaxone	16	>64	1.3	2.2	5.1	14.2	35	25.3	39.8	
	Imipenem	0.5	>16	59.2	74.9	81.8	85.9	81.8	5.4	12.9	
	Levofloxacin	2	>8	45.3	49.2	55.3	68	55.3	12.7	32	
	Minocycline	≤0.5	4	65.9	81.6	86.4	91.8	91.8	5.7	2.5	
	PipTazo	8	>128	33.2	39	42.9	46	61.1	10.3	28.6	
	<i>P. aeruginosa</i> (1,236)	Tigecycline	8	>16	1.5	3.2	7.8	25.4	na	na	na
		Amikacin	4	16	1.1	6.6	40.7	75.8	89	4.5	6.5
		Cefepime	4	32	1.7	11.2	36.8	56.5	75.8	0	24.2
		Ceftazidime	≤8	32	0	0	0	0	78.2	0	21.8
Ceftriaxone		64	>64	0.6	1.5	2.9	7.9	18.3	25	56.7	
Imipenem		1	16	22.6	63	75.3	82	82	7.7	10.2	
Levofloxacin		1	>8	44.2	57.7	67	74	57.7	9.3	33	
Minocycline		>16	>16	0.3	0.9	2.2	6.6	6.6	14.6	78.7	
PipTazo		4	128	3.6	7	29	61.8	89.4	0	10.6	

^a Includes 120 ESBL-producing *E. coli* strains.

^b Includes 142 *K. pneumoniae* strains and 14 *K. oxytoca* strains.

^c ESBL producing *E. coli*, *K. pneumoniae* and *K. oxytoca*

* Interpretive criteria as defined by EUCAST, where available; CLSI breakpoints, where available, were used where no EUCAST breakpoints exist; na = not available.

Table 2. In vitro activity of tigecycline and comparative agents against selected gram-positive organisms.

Organism (n)		MIC		Cumulative % inhibited				%S*	%I	%R	
		(mcg/ml)		at MIC							
		MIC ₅₀	MIC ₉₀	0.5	1	2	4				
<i>S. aureus</i> ^a (1,340)	Tigecycline	0.12	0.25	100				100	0	0	
	AmoxClav	1	>8	40.2	68.5	77.2	81.2	81.2	0	18.8	
	Ampicillin	8	>16	20.9	28	36.3	46.5	16.8	0	83.2	
	Ceftriaxone	4	>64	0.5	6.3	48.2	74.3	0.2	0	99.8	
	Imipenem	0.25	16	84.6	86.2	87.7	88.8	88.8	0.5	10.7	
	Levofloxacin	0.12	8	75.1	76.2	78	85.1	76.2	1.8	22	
	Linezolid	2	4	2.6	28.6	89.3	100	100	0	0	
	Minocycline	≤0.25	0.5	92.6	93.9	95	98.9	98.9	1	0.1	
	Penicillin	8	>8	20.4	25.7	31.6	39.6	13.9	0	86.1	
	PipTazo	1	>16	42.4	71.1	75.9	80	82.5	0	17.5	
	Vancomycin	0.5	1	50.6	95.1	100	100	100	0	0	
	<i>S. aureus</i> (MR) (337)	Tigecycline	0.12	0.25	100				100	0	0
		AmoxClav	>8	>8	1.8	4.2	11.6	25.2	25.2	0	74.8
Ampicillin		>16	>16	0.6	2.7	5.6	7.4	0	0	100	
Ceftriaxone		>64	>64	0	0.6	1.5	4.2	0	0	100	
Imipenem		2	>16	39.4	45.2	50.6	55.2	55.2	2.1	42.7	
Levofloxacin		8	32	9.2	10.4	14.2	41.8	10.4	3.9	85.8	
Linezolid		2	2	0	30.6	92	100	100	0	0	
Minocycline		≤0.25	4	76.6	78.6						